Results 171 to 180 of about 1,224,792 (212)
Some of the next articles are maybe not open access.
Sleep
In the phase 3 REST-ON clinical trial, extended-release, once-nightly sodium oxybate (ON-SXB) demonstrated a safety profile consistent with the known oxybate safety profile, with adverse drug reactions (ADRs) primarily related to tolerability.
Bruce C. Corser +8 more
semanticscholar +1 more source
In the phase 3 REST-ON clinical trial, extended-release, once-nightly sodium oxybate (ON-SXB) demonstrated a safety profile consistent with the known oxybate safety profile, with adverse drug reactions (ADRs) primarily related to tolerability.
Bruce C. Corser +8 more
semanticscholar +1 more source
Clinical Therapeutics
PURPOSE Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness (EDS) and can occur with or without cataplexy. Once-nightly sodium oxybate (ON-SXB) is approved for the treatment of cataplexy or EDS in patients 7 years of
Morgan T. Lavender +8 more
semanticscholar +1 more source
PURPOSE Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness (EDS) and can occur with or without cataplexy. Once-nightly sodium oxybate (ON-SXB) is approved for the treatment of cataplexy or EDS in patients 7 years of
Morgan T. Lavender +8 more
semanticscholar +1 more source
1432 A Case of Breakthrough Sleepiness on Sodium Oxybate with Excessive Slow Wave Sleep
SleepSodium oxybate is commonly used in disorders of hypersomnia to decrease excessive daytime sleepiness and decrease disrupted sleep. The medication acts by increasing slow wave sleep through agonizing GABA-B receptors.
Brian A Soto, Katie Tribuls, R. Shah
semanticscholar +1 more source
Sleep
Sodium oxybate (SXB) is a central nervous system depressant used to treat narcolepsy and has the potential to cause respiratory depression. Registrational trials of SXB have generally excluded patients with respiratory depression, including those ...
Richard Bogan +5 more
semanticscholar +1 more source
Sodium oxybate (SXB) is a central nervous system depressant used to treat narcolepsy and has the potential to cause respiratory depression. Registrational trials of SXB have generally excluded patients with respiratory depression, including those ...
Richard Bogan +5 more
semanticscholar +1 more source
Sleep
The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
H. Merius +5 more
semanticscholar +1 more source
The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
H. Merius +5 more
semanticscholar +1 more source
Expert Review of Neurotherapeutics, 2006
Sodium oxybate (Xyrem), also known as gamma-hydroxybutyric acid, is the only therapeutic specifically approved in the USA for the treatment of cataplexy in narcolepsy. The US FDA has recently expanded its indication to include excessive daytime sleepiness associated with narcolepsy.
openaire +2 more sources
Sodium oxybate (Xyrem), also known as gamma-hydroxybutyric acid, is the only therapeutic specifically approved in the USA for the treatment of cataplexy in narcolepsy. The US FDA has recently expanded its indication to include excessive daytime sleepiness associated with narcolepsy.
openaire +2 more sources